Navicixizumab
drug drugOn this page
Also known as Omp 305b83OMP-305B83
Summary
Navicixizumab (CHEMBL3989984) is a phase-3 clinical-stage antibody; indicated across 4 conditions including neoplasm and ovarian carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Indications: 4 conditions
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3989984 |
| Name | Navicixizumab |
| Type | Antibody |
| Max phase | 3 |
Also known as: Navicixizumab, Omp 305b83, OMP-305B83, NAVICIXIZUMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
| ovarian carcinoma | 1 | MONDO:0005140 | EFO:0001075 |
| fallopian tube carcinoma | 1 | MONDO:0006206 | EFO:1000251 |
| peritoneal neoplasm | 1 | MONDO:0006901 | EFO:1001100 |
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 3 |
| PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05043402 | PHASE3 | UNKNOWN | A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer |
| NCT05453825 | PHASE2 | UNKNOWN | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors |
| NCT02298387 | PHASE1 | COMPLETED | A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors |
| NCT03030287 | PHASE1 | COMPLETED | A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer |
| NCT03035253 | PHASE1 | TERMINATED | A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.